XM does not provide services to residents of the United States of America.

Agilent Q4 Revenue USD 1,701 Million Vs. IBES Estimate USD 1,672 Million



<html xmlns="http://www.w3.org/1999/xhtml"> <head> <meta content="HTML Tidy for HTML5 for Linux version 5.2.0" name="generator"/> <title>BRIEF-Agilent Q4 Revenue USD 1,701 Million Vs. IBES Estimate USD 1,672 Million</title></head> <body>

Nov 25 (Reuters) - Agilent Q4 income from operations USD 408 million.

  • Q4 net income USD 351 million
  • Q4 pretax profit USD 401 million vs. IBES estimate USD 473.1 million
  • Q4 EPS USD 1.22
  • Q4 adjusted net income USD 418 million vs. IBES estimate USD 408.9 million
  • outlook Q1 revenue USD 1,650-1,680 million
  • outlook FY adjusted EPS USD 5.54-5.61
  • outlook FY revenue USD 6,790-6,870 million
  • outlook Q1 adjusted EPS USD 1.25-1.28
</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.